Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a report issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on shares of Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price on the stock.

Lipocine Stock Performance

Shares of LPCN opened at $4.88 on Wednesday. Lipocine has a fifty-two week low of $2.76 and a fifty-two week high of $11.79. The business has a 50-day moving average of $5.09 and a 200 day moving average of $5.28. The firm has a market cap of $26.10 million, a P/E ratio of -6.42 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, research analysts predict that Lipocine will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.